RNAC Stock Analysis: Cartesian Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 311m USD | 12M Return: -6.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.15M
Qual. Beats: 0
Rev. Trend: -77.6%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) is a clinical-stage biotechnology company headquartered in Frederick, Maryland, developing mRNA cell therapies for autoimmune diseases and cancer. The companys lead candidate, Descartes-08, is an autologous mRNA CAR-T therapy targeting BCMA, currently in Phase 2b trials for generalized myasthenia gravis and systemic lupus erythematosus, with rare pediatric disease designation for juvenile dermatomyositis. Cartesian is also advancing Descartes-15, a BCMA-directed mRNA CAR-T in Phase 1 development for multiple myeloma.
As a clinical-stage company, Cartesian has no approved products and is likely funded through a combination of equity offerings, grants, and partnerships typical of the pre-commercial biotechnology sector. The companys use of mRNA-based CAR-T represents a differentiated approach within the cell therapy field, as mRNA engineering enables transient CAR expression without permanent genetic modification, which may offer safety and retreatment advantages over conventional viral-vector-based CAR-T platforms.
- Descartes-08 Phase 2b myasthenia gravis data readout
- Descartes-15 Phase 1 multiple myeloma trial advances
- Dilution risk persists as small-cap clinical-stage biotech without product revenue
| Net Income: -151.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.50 > 0.02 and ΔFCF/TA -40.39 > 1.0 |
| NWC/Revenue: 5.98k% < 20% (prev 497.8%; Δ 5.48k% < -1%) |
| CFO/TA -0.25 > 3% & CFO -73.0m > Net Income -151.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.65 > 1.5 & < 3 |
| Outstanding Shares: last quarter (26.9m) vs 12m ago 3.68% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.51% > 50% (prev 8.35%; Δ -7.84% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.37 (Total Current Assets 122.0m - Total Current Liabilities 15.9m) / Total Assets 288.4m |
| B: -2.99 (Retained Earnings -861.6m / Total Assets 288.4m) |
| C: -0.46 (EBIT TTM -161.0m / Avg Total Assets 348.8m) |
| D: -0.34 (Book Value of Equity -148.1m / Total Liabilities 436.5m) |
| Altman-Z'' = -10.78 = D |
| DSRI: 2.85 (Receivables 261k/1.76m, Revenue 1.77m/34.2m) |
| GMI: 1.0 (GM 100.0% / 100.0%) |
| AQI: 1.02 (AQ_t 0.52 / AQ_t-1 0.51) |
| SGI: 0.05 (Revenue 1.77m / 34.2m) |
| TATA: -0.27 (NI -151.8m - CFO -73.0m) / TA 288.4m) |
| Beneish M = -2.21 (Cap -4..+1) = BB |
As of July 08, 2026, the stock is trading at USD 10.05 with a total of 138,642 shares traded. Over the past week, the price has changed by +4.25%, over one month by +71.50%, over three months by +60.03% and over the past year by -6.69%.
Current recommended Stop Loss: 8.50 (which is 15.4% or 1.6 ATR below the current price).
Cartesian Therapeutics has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy RNAC.
- StrongBuy: 4
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 34.6 | 244% |
P/E Forward = 25.0627
P/S = 175.2959
P/B = 597.9765
Revenue TTM = 1.77m USD
EBIT TTM = -161.0m USD
EBITDA TTM = -158.5m USD
Long Term Debt = 7.67m USD (estimated: total debt 11.9m - short term 4.19m)
Short Term Debt = 4.19m USD (from shortTermDebt, last quarter)
Debt = 11.9m USD (from shortLongTermDebtTotal, last quarter) (leases 11.9m already included)
Net Debt = -106.8m USD (calculated: Debt 11.9m - CCE 118.6m)
Enterprise Value = 204.4m USD (311.2m + Debt 11.9m - CCE 118.6m)
Interest Coverage Ratio = unknown (Ebit TTM -161.0m / Interest Expense TTM 0.0)
EV/FCF = -1.43x (Enterprise Value 204.4m / FCF TTM -143.3m)
FCF Yield = -70.13% (FCF TTM -143.3m / Enterprise Value 204.4m)
FCF Margin = -8.07k% (FCF TTM -143.3m / Revenue TTM 1.77m)
Net Margin = -8.55k% (Net Income TTM -151.8m / Revenue TTM 1.77m)
Gross Margin = unknown ((Revenue TTM 1.77m - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 0.71 (Enterprise Value 204.4m / Total Assets 288.4m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 11.9m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -127.2m (EBIT -161.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.96 (Total Current Assets 122.0m / Total Current Liabilities 17.5m)
Debt / Equity = -0.08 (negative equity) (Debt 11.9m / totalStockholderEquity, last quarter -148.1m)
Debt / EBITDA = 0.67 (negative EBITDA) (Net Debt -106.8m / EBITDA -158.5m)
Debt / FCF = 0.75 (negative FCF - burning cash) (Net Debt -106.8m / FCF TTM -143.3m)
Total Stockholder Equity = -78.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -43.52% (Net Income -151.8m / Total Assets 288.4m)
RoE = 194.1% (negative equity) (Net Income TTM -151.8m / Total Stockholder Equity -78.2m)
RoCE = 228.3% (negative capital employed) (EBIT -161.0m / Capital Employed (Equity -78.2m + L.T.Debt 7.67m))
RoIC = -45.98% (negative operating profit) (NOPAT -127.2m / Invested Capital 276.5m)
WACC = 11.64% (E(311.2m)/V(323.0m) * Re(12.08%) + D(11.9m)/V(323.0m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 12.08% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 82.22 | Cagr: 108.0%
[DCF] Fair Price = unknown (Cash Flow -143.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.26 | # QB: 0
Revenue Correlation: -77.60 | Revenue CAGR: -74.95% | SUE: -0.01 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.65 | Chg30d=+4.41% | Revisions=+25% | Analysts=1
EPS next Quarter (2026-09-30): EPS=-0.69 | Chg30d=-53.33% | Revisions=-25% | Analysts=1
EPS current Year (2026-12-31): EPS=-3.35 | Chg30d=-55.81% | Revisions=-25% | GrowthEPS=+32.9% | GrowthRev=-80.3%
EPS next Year (2027-12-31): EPS=-2.68 | Chg30d=-58.58% | Revisions=-25% | GrowthEPS=+20.0% | GrowthRev=-27.3%